Stage
Phase
Status
Reset Filter
PROSTATE: POST-PROSTATECTOMY: PSA RECURRENCE: NRG GU 006

A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer

VIEW TRIAL ON CLINICALTRIALS.GOV
Malignancy

Prostate Cancer

Stage

Stage 3

Phase

Phase 2

Status

Open to Enrollment

Line Of Therapy

1st Line post recurrence

Investigational Agent

Radiation +/- apalutamide

Drug Class

Androgen receptor inhibitor

PI

Dan Vaena, MD

Sponsor

NRG Oncology

Path

Adenocarcinoma

Key Eligibility Criteria Details
  • Prostate adenocarcinoma
  • Post-prostatectomy (within last 10 years)
  • Detectable serum PSA (between 0.1 and 1.0 ng/mL) at study entry
  • Any of following
    • Gleason score 7-10
    • >= T3a disease
    • PSA never became undetectable following prostatectomy
  • No nodal involvement
  • KPS 70-100
  • Availability of tissue
  • Prior ADT allowed if previously given for <90 days
  • GFR >35
  • No prior invasive malignancy except in-situ disease, stage I resected melanoma, or disease free for at least 2 years
  • No prior chemotherapy for prostate cancer
  • No prior radiation that would result in overlap
  • No history or predisposition to seizures
  • No IBD
  • No severe CAD
MOLECULARLY TARGETED: FGFR-mutant or fusions: FGFR inhibitor: FIGHT-207

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

VIEW TRIAL ON CLINICALTRIALS.GOV
Malignancy

Solid Tumors: Breast, Lung (NSCLC), Colon, Prostate, Bladder, Kidney, Esophagus, Stomach (Gastric), Liver (HCC), Cervical, Endometrial, Ovarian, Skin, Head and Neck (SCCHN), Bladder, Kidney (renal cell), Pancreatic, Rectal, Brain (GBM, glioblastoma)

Stage

Stage 4

Phase

Phase 2

Status

Open to Enrollment

Line Of Therapy

Following all effecive therapy (late line)

Investigational Agent

Pemigatinib

Drug Class

FGFR inhibitor

PI

Dan Vaena, MD

Sponsor

Incyte Corporation

Path

FGFR 1,2,3 mutated or FGFR 1,2,3 fusion/translocation

Key Eligibility Criteria Details
  • Metastatic or surgically unresectable solid tumor
  • Measurable disease
  • Documentation of an FGFR1-3 gene mutation or translocation
  • At least 1 prior line of therapy with progression
  • No other therapy available likely to provide clinical benefit
  • ECOG PS 0-2
  • No other FGFR inhibitors within last 6 months
  • No clinically significant corneal or retinal disorder
  • No untreated CNS disease (except primary brain cancer)
  • No additional malignancy at current time requiring active treatment
  • No history of calcium or phosphate disorder or systemic mineral imbalance
  • No clinically significant cardiac disease
  • No active HBV/HCV
  • No known HIV
MOLECULARLY TARGETED: Metastatic; Solid Tumors: HER2mt or ERBB4mt: SUMMIT

An open-label, multicenter, multinational, phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification

VIEW TRIAL ON CLINICALTRIALS.GOV
Malignancy

Bladder, Breast, Brain (GBM), Head and Neck, Prostate, Kidney (Renal Cell), Melanoma, Ovarian, Endometrial (Uterine), Cervical, Gastric, Pancreatic, Hepatocellular (HCC), Esophageal, lymphoma, sarcoma

Stage

Stage 4

Phase

Phase 2

Status

Open to Enrollment

Line Of Therapy

Any (provided no curative therapy available)

Investigational Agent

Neratinib

Drug Class

pan-HER TKI

PI

Lee Schwartzberg, MD

Sponsor

Puma Biotechnologies

Path

HER2 (ERBB2) mutation or HER4 (ERBB4 mutation), or EGFR ex. 18 mutated lung cancer

Key Eligibility Criteria Details
  • Histologically confirmed cancer for which no curative therapy exists
  • Documented HER2 (ERBB2) or HER4 (ERBB4)  mutation in any malignancy or EGFR ex 18 mutations in lung cancer.
    • Currently CLOSED cohorts include: HER2mt lung, colorectal, and biliary
  • At least one measurable or evaluable lesion
  • LVEF >/=50%
  • ECOG PS 0-2
  • No prior treatment with ERBB2 (HER2) directed TKIs (eg lapatinib, afatinib, neratinib)
  • No symptomatic or unstable brain mets (stable are allowed)
  • No cumulative prior anthracycline dose >450mg/m2 doxorubicin or equivalent
  • No uncontrolled cardiac disease
  • No chronic diarrheal disorder
ADVANCED SOLID TUMORS: PHASE 1: ADENOSINE PATHWAY: TTX-030-002

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors

VIEW TRIAL ON CLINICALTRIALS.GOV
Malignancy

Prostate, Kidney, Head and Neck, Colon Rectum, Gastric, Esophagus

Stage

Stage 4

Phase

Phase 1

Status

Open to Enrollment

Line Of Therapy

late line

Investigational Agent

TTX-030, budigalimab

Drug Class

Anti CD-39, anti-PD1

PI

Dan Vaena, MD

Sponsor

Tizona Therapeutics

Path

Any

Key Eligibility Criteria Details
  • Advanced Solid Malignancy
  • Fresh and/or archival tumor tissue
  • Evidence of measurable disease (except for prostate)
  • Life expectancy >12 weeks
  • ECOG PS 0-1
  • No therapeutic anticoagulation
  • no history of autoimmune disease
  • No uncontrolled intercurrent illness
  • No HTN >150/90 despite optimal management
  • No active CNS mets
  • No other malignancies within 3 years
  • No autoimmune toxicity >Grade 3 from prior immunotherapy
X